• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

Intarcia Therapeutics takes another run at FDA approval

October 15, 2019 By Sean Whooley

Intarcia Therapeutics

Intarcia Therapeutics said last week that the FDA accepted its new drug application resubmission for ITCA 650 for the treatment of Type 2 diabetes mellitus. The Boston-based company originally resubmitted the NDA on Sept. 9. FDA told the company that it considered the NDA resubmission a complete class 2 response. The Prescription Drug User Fee […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants Tagged With: FDA, Intarcia Therapeutics

Abbott inks inks diabetes tech partnerships with Tandem Diabetes, Omada Health

October 15, 2019 By Sean Whooley

Abbott logo updated

Abbott (NYSE:ABT) said today that it has entered into an agreement with Tandem Diabetes Care (NSDQ:TNDM) to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The news comes one day after Abbott announced a partnership with Omada Health to pair Abbott’s FreeStyle Libre continuous glucose monitoring system with Omada’s digital care program. Tandem designed its […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: abbott, Omada Health, Tandem Diabetes Care

OcuMedic, Gelest ink drug-delivering contact lens deal

October 9, 2019 By Sean Whooley

OcuMedic said today that it entered into an exclusive supply agreement and picked up a strategic investment from Gelest for its proprietary drug-eluting soft contact lens of an undisclosed amount. Under the terms of the agreement, Morrisville, Pa.-based Gelest is set to manufacture and supply OcuMedic’s key chemistry components used in the controlled release of […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic Tagged With: Gelest, OcuMedic

BioCardia wins CE Mark renewal for Helix, Morph catheters

October 9, 2019 By Sean Whooley

BioCardia

BioCardia (OTC:BCDA) said yesterday that it won CE Mark renewal for its Helix biotherapeutic delivery catheter and Morph universal deflectable guide catheter for delivery of biotherapeutics to the heart. With the renewed CE Mark, BioCardia said it can continue supporting partners outside the U.S. and move forward with commercial sales of the Helix and Morph systems […]

Filed Under: Cardiovascular, Featured, Regenerative Medicine, Regulatory/Compliance Tagged With: BioCardia

Walmart brings One Drop wireless glucose meter kit to stores

October 9, 2019 By Sean Whooley

One Drop

One Drop said yesterday that its wireless glucose meter kit and supplies are now available at hundreds of Walmart stores in the U.S. The kits for sale at the retail store include a Bluetooth glucose meter, lancing device, carry case, test strips and lancets, along with a year of free access to One Drop’s certified […]

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: One Drop

Haselmeier licenses Axis-D pen injector to Stevanato Group

October 7, 2019 By Sean Whooley

Haselmeier said today that it entered into an exclusive agreement with Stevanato Group to license the Axis-D pen injector and intellectual property for the development, manufacturing and supply of the device for diabetes care. Haselmeier’s Axis-D auto-injector pen is approved for use by the European Medical Agency and the FDA, among other regulatory bodies. The […]

Filed Under: Auto-injectors, Diabetes, Featured, Mergers & Acquisitions Tagged With: haselmeier, Stevanato Group

Intersect ENT’s Ascend study misses endpoint

October 7, 2019 By Sean Whooley

Intersect ENT updated

Intersect ENT (NSDQ:XENT) shares plunged today after the company said it failed to meet the primary endpoint in a study of its Ascend investigational drug-coated sinus balloon. The 70-person, randomized, double-blind trial was designed to compared treatment with Intersect ENT’s DCB when randomized against an uncoated balloon control. The study missed the primary endpoint, frontal sinus […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Otolaryngology Ear, Nose & Throat Tagged With: Intersect ENT Inc., SVB Leerink

GSK seeks additional asthma indication for Trelegy Ellipta

October 3, 2019 By Sean Whooley

GlaxoSmithKline, Innoviva, Trelegy Ellipta

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said yesterday that they filed a supplemental New Drug Application with the FDA, seeking an additional indication for GSK’s Trelegy Ellipta inhaler for the treatment of asthma in adults. The once-daily, single-inhaler triple-therapy device received FDA approval for the treatment of chronic obstructive pulmonary disease in September 2017. Trelegy Ellipta has not […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory Tagged With: GlaxoSmithKline plc, Innoviva

Frequency Therapeutics prices $84m IPO

October 3, 2019 By Sean Whooley

Frequency Therapeutics updated logo

Frequency Therapeutics said yesterday that it priced its initial public offering at roughly $84 million. The 6-million-share offering priced at $14 per share and includes a 30-day underwriters option on another 900,000 shares that’s worth $12.6 million, the Woburn, Mass.-based company said. Frequency said it expected to begin trading the shares on the NASDAQ exchange […]

Filed Under: Featured, Funding Roundup, Initial Public Offering (IPO), Otolaryngology Ear, Nose & Throat, Wall Street Beat Tagged With: Frequency Therapeutics

Boehringer Ingelheim touts Spiolto Respimat inhaler data

October 2, 2019 By Sean Whooley

Boehringer Ingelheim

Boehringer Ingelheim said yesterday that results from a study of its Spiolto Respimat inhaler showed benefits including improving symptoms and lung function in treating chronic obstructive pulmonary disease. The Spiolto Respimat is a soft-mist inhaler designed for the treatment of airflow obstruction in patients with COPD. A pooled analysis exploring COPD treatment with the tiotropium-based […]

Filed Under: Clinical Trials, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 162
  • Page 163
  • Page 164
  • Page 165
  • Page 166
  • Interim pages omitted …
  • Page 168
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS